Tumor antigens Bfa5 for prevention and/or treatment of cancer
The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. MTKRKKTINLNIQDAQKRTALHWACVNGHEEVVTFLVDRKCQLDVLDG EHRTPLMKALQCHQEACANILIDSGADINLVDVYGNMALHYAVYSEIL SVVAKLLSHGAVIEVHNKASLTPLLLSITKRSEQIVEFLLIKNANANA VNKYKCTALMLAVCHGSSEIVGMLLQQNVDVFAADICGVTAEHYAVTC GFHHIHEQIMEYIRKLSKNHQNTNPEGTSAGTPDEAAPLAERTPDTAE SLVEKTPDEAAPLVERTPDTAESLVEKTPDEAASLVEGTSDKIQCLEK ATSGKFEQSAEETPREITSPAKETSEKFTWPAKGRPRKIAWEKKEDTP REIMSPAKETSEKFTWAAKGRPRKIAWEKKETFVKTGCVARVTSNKTK VLEKGRSKMIACPTKESSTKASANDQRFPSESKQEEDEEYSCDSRSLF ESSAKIQVCIPESIYQKVMEINREVEEPPKKPSAFKPAIEMQNSVPNK AFELKNEQTLRADPMFPPESKQKDYEENSWDSESLCETVSQKDVCLPK ATHQKEIDKINGKLEESPNKDGLLKATCGMKVSIPTKALELKDMQTFK AEPPGKPSAFEPATEMQKSVPNKALELKNEQTWRADEILPSESKQKDY EENSWDTESLCETVSQKDVCLPKAAHQKEIDKINGKLEGSPVKDGLLK ANCGMKVSIPTKALELMDMQTFKAEPPEKPSAFEPAIEMQKSVFNKAL ELKNEQTLRADEILPSESKQKDYEESSWDSESLCETVSQKDVCLPKAT HQKEIDKINGKLEESPDNDGFLKAPCRMKVSIPTKALELMDMQTFKAE PPEKPSAFEPAIEMQKSVPNKALELKNEQTLRADQMFPSESKQKKVEE NSWDSESLRETVSQKDVCVPKATHQKEMDKISGKLEDSTSLSKILDTV HSCERARELQKDHCEQRTGKMEQMKKKFCVLKKKLSEAKEIKSQLENQ KVKWEQELCSVRLTLNQEEEKRRNADILNEKIREELGRIEEQERKELE VKQQLEQALRIQDIELKSVESNLNQVSHTHENENYLLHENCMLKKEIA MLKLEIATLKHQYQEKENKYFEDIKILKEKNAELQMTLKLKEESLTKR ASQYSGQLKVLIAENTMLTSKLKEKQDKEILEAEIESHHPRLASAVQD HDQIVTSRKSQEPAFHIAGDACLQRKMNVDVSSTIYNNEVLHQPLSEA QRKSKSLKINLNYAGDALRENTLVSEHAQRDQRETQCQMKEAEHMYQN EQDNVNKHTEQQESLDQKLFQLQSKNMWLQQQLVHAHLLADNKSKITI DIHFLERKMQHHLLKEKNEEIFNYNNHLKNRIYQYEKEKAETENS
1. An isolated peptide selected from the group consisting of SEQ ID NO.:7, SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, and SEQ ID NO.:12, the peptide being immunogenic as determined by ELISPOT analysis of human T-cell cultures or human T cell cytotoxicity assay.
2. A composition comprising an isolated peptide of claim 1 and a pharmaceutically acceptable carrier.
3. The isolated peptide LMDMQTFKA (SEQ ID NO.:7).
4. A composition comprising the isolated peptide of claim 3 in a pharmaceutically acceptable carrier.
5. A composition for inducing an immune response in a host comprising the isolated peptide of claim 3 and at least one isolated peptide selected from the group consisting of SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:99, SEQ ID NO.:100, SEQ ID NO.:101, SEQ ID NO.:102, SEQ ID NO.:103, and SEQ ID NO.:104, and a pharmaceutically acceptable carrier.
6. A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the isolated peptide of claim 3 .
7. A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the composition of claim 4 .
8. A method for inducing an immune response in a host against the tumor antigen BFA5 (SEQ ID NO.: 6) comprising administering to the host the composition of claim 5 .